Corvus Pharmaceuticals (CRVS) Stock Price & Analysis

CRVS$10.60-0.04 -0.38%
BiotechnologyValue StockGrowth Stock
Compare
Market cap$894.14MEnterprise value$872.25MRevenue (TTM)$0Market position—

Score

70
Bullish
Value
62
Quality
47
Growth
100

AI Analysis

Snapshot

Corvus Pharmaceuticals is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 70/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~155% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

62
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

47
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Corvus Pharmaceuticals, Inc. (CRVS) last printed $10.60. Equity value is $894.14M. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00

About

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.

Corvus Pharmaceuticals (CRVS) Stock Price & Analysis

CRVS price $10.60 -0.04 -0.38%

Ticker
CRVS
Price
$10.60
Change
-0.04 -0.38%
Market cap
$894.14M
Forward P/E
79.55
Dividend yield
0.00%
Beta
0.86
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
70
Value
62
Quality
47
Growth
100

Stocklytics score rationale: value 62, quality 47, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener